Bone MicroArchitecture in Acromegaly

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2016

Primary Completion Date

December 21, 2019

Study Completion Date

December 21, 2019

Conditions

AcromegalyOsteoporosis Risk

Interventions

DRUG

Pegvisomant

Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.

Trial Locations (1)

Neuroendocrine Unit and Pituitary Center, Columbia University, New York